NCT04098237View on ClinicalTrials.gov

Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

January 12, 2024

Study Completion Date

January 31, 2027

Conditions
Pancreatic Adenocarcinoma
Interventions
DRUG

Pancrelipase

Pancrelipase delayed-release capsules

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

All Listed Sponsors
collaborator

VIVUS LLC

INDUSTRY

lead

Andrew Hendifar, MD

OTHER